Eli Hazum

Medica Venture Partners (Medica Venture Partners) is a venture capital firm founded in 1995 by Yuval Binur, Ehud Geller and Jonathan Fleming. The firm is headquartered in Israel.

Research Triangle Foundation is located in the Research Triangle Park (RTP), which is the largest research park in the United States. The RTP is located in Raleigh, NC, which was historically a southern economy dependent on tobacco, textiles, and furniture manufacturing. The park houses hundreds of companies, including science and technology firms, government agencies, academic institutions, startups, and nonprofits. The foundation offers meeting and office spaces, educational opportunities, and networking events. However, the area has since become a hub for innovation and technology, attracting a highly educated workforce.

Ester Neurosciences Ltd. engages in the research and development of screening assays. The company was founded on June 17, 1997 and is headquartered in Tel Aviv, Israel.

Collgard Biopharmaceuticals, the tissue therapeutics company, is developing drug treatments that target disease progression by directly influencing the tissue regeneration process. Central to Collgard's novel approach is its lead drug candidate, Tempostatin (Halofuginone hydrobromide). Tempostatin is a multi-indication, small-molecule drug candidate that has been identified by the company as influencing a 'master switch' in the body's tissue repair process. As a potent and selective regulator of stromal cell activation, cell migration and excessive collagen type I synthesis, Tempostatin makes it possible to harness and direct the tissue repair process for treating diseases acting at the tissue level. Collgard is developing therapeutic solutions for several clinical indications with significant unmet clinical needs. These solutions are based on highly specific control of the tissue repair process. Current programs target the following indications vascular restenosis, end-organ fibrosis, selected cancers and dermal fibroproliferative disorders. Tempostatin holds exceptional promise based on addressing a fundamental underlying pathological process that is not accessible to other current therapeutic approaches. In developing Tempostatin, Collgard seeks to offer novel therapeutic solutions as well as extend the effectiveness of existing therapies. Founded in 1996, Collgard Biopharmaceuticals is a privately held, clinical stage company, led by a global team of medical and drug development experts based in Atlanta and Tel Aviv. Scientific and clinical collaborators include The Mayo Clinic, the U.S. NCI, the EORTC, and Harvard Medical School. Collgard was founded by Medica Venture Partners. Additional investors include Mayo Medical Ventures, Denali Ventures, Yozma Group, and Comsor.

Regentis Biomaterials Ltd. engages in the research and development of proprietary hydrogels for local repair of damaged cartilage and bone. Its product is GelrinC. The company was founded by Dror Seliktar and Tal Yehiel on September 1, 2004 and is headquartered in Or-Akiva, Israel.

Biotechnology General (Israel) Ltd. manufactures and markets pharmaceutical products. Its products include Aminopeptidase B, Euflexxa, Zomacton, BioTropin, and Carboxypeptidase. The firm has operations in Europe, Japan, and the United States. The company was founded in 1980 and is headquartered in Kiryat Malachi, Israel